Cancer

LIH has built up a strong expertise in selected cancer types, including brain cancer, haematological malignancies and gastro-intestinal cancers.


LIH has built up a strong expertise in selected cancer types, including brain cancer, haematological malignancies and gastro-intestinal cancers.

For brain cancer, LIH focuses specifically on glioblastoma (GBM) and brain metastases, leveraging on an in-house collection of more than 500 cross-sectional patient-derived samples.

In terms of haematological malignancies, LIH’s research activities concentrate on chronic lymphocytic leukaemia and are supported by an in-house collection of over 300 cross-sectional and longitudinal patient-derived samples.

A third priority cancer category consists of gastro-intestinal cancers (GIC), for which a collection of samples from patients is already in its pilot phase, in parallel to the Personalised Functional Profiling (PFP) project dedicated to GBM and GIC.

The goal is to understand the immunological aspects of the onset and progression of these diseases, as well as advance immuno-oncology, from the prediction of responses to immune therapies, to the development of novel immunotherapy targets.

In addition, LIH investigates mechanistic processes that are fundamental for cancer initiation and progression, such as cancer metabolism, cancer genetics/epigenetics, invasion and metastasis and therapeutic resistance mechanisms.

The ultimate aim is to deepen the understanding and improve the treatment of cancers that affect large patient populations, thereby maximising the clinical impact of LIH’s translational research.


LIH research groups

Several LIH research groups are currently working on this highly transversal priority area, integrating a broad set of in-house methodologies and capacities — ranging from ‘-omic’ approaches to epidemiology, exposure measurement and digital health expertise — thus studying the disease from different angles in a truly holistic way.

Discover the different research groups below.